Immunomodulatory therapy for the management of severe COVID-19. Beyond the anti-viral therapy: A comprehensive review
Article
[키워드] ACE-2, Angiotensin-Converting Enzyme-2
acute respiratory distress syndrome
AD, Autoimmune diseases
ADE, antibody dependent enhancement
ADRS, Acute distress respiratory syndrome
APC, antigen-presenting cells
aPL, Antiphospholipid antibodies
CD, Cluster of differentiation or cluster of designation or classification determinant
CDC, Centres for Disease Control
COVID-19
COVID-19, Coronavirus disease 2019
CQ, Chloroquine
CyA, Cyclosporine A
Cytokine storm
FDA, Food and Drugs Administration
GCS, Glucocorticoids
HCQ, hydroxychloroquine
HPS, Haemophagocytic syndrome
IFNγ, interferon gamma
IL, interleukin
immunosuppressive
IVIG, Intravenous immunoglobulins
JAK, Janus-Kinase family of enzymes (JAK1, JAK2, JAK3, TYK2)
LMWH, Low-molecular weight heparin
MAS, macrophage activation syndrome
MDA5, Melanoma differentiation-associated gene 5
MERS-CoV, Middle East respiratory syndrome coronavirus
MHC-II, Major histocompatibility type-II
mTOR, Mammalian target of rapamycin
NF-kβ, Nuclear Factor-Kβ
NHC, National Health Council
NK, natural killer cells
PIC, Pulmonary intravascular coagulation
PTE, Pulmonary thromboembolism
RA, Rheumatoid arthritis
SARS-CoV-2
SARS-COV-2, severe acute respiratory syndrome coronavirus-2
SLE, systemic lupus erythematosus
TCZ, tocilizumab
TGF-β, Transforming growth factor-beta
TLR, Toll-like receptor
TNF-α, Tumour necrosis factor-alpha
TRAASVIR, Thrombotic Risk Associated with Antiphospholipid Syndrome after Viral infection
TRALI, Transfusion-related acute lung injury
Treatment
Tregs, Regulatory T-cells
WHO, World Health Organization
[DOI] 10.1016/j.autrev.2020.102569 PMC 바로가기 [Article Type] Article
[DOI] 10.1016/j.autrev.2020.102569 PMC 바로가기 [Article Type] Article